HUANG Ruimin
Principal Investigator
Molecular Imaging Center;Institutional Center for Shared Technologies and Facilities of SIMM, CAS
Personal Homepage
CONTACT
rmhuang@simm.ac.cn
201203
555 Zuchongzhi Road, Zhang Jiang Hi-Tech Park, Pudong, Shanghai, P.R.China.
Biography
Dr. HUANG Ruimin obtained her Ph.D. in 2004 from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, and received her postdoctoral training at Memorial Sloan Kettering Cancer Center. She was promoted to Research Associate in 2009 and then to Senior Research Scientist in 2012. In March 2016, Dr. Huang was recruited as a professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
Dr. Huang’s research interests focus on molecular imaging in drug development and functional analysis of cancer-related genes. These results have been published in top-tier interdisciplinary journals, such as Science Translational Medicine, Cancer Research, Clinical Cancer Research, and Theranostics.
Education
1999.09 - 2004.07 Ph.D. in Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
1994.09 - 1999.07 B.S. in Biological Sciences, University of Science and Technology of China, Hefei, China
Work Experience
2016.03 - present Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
2004.10 - 2016.03 Senior Research Scientist/Research Associate/Research Scholar/ Research Fellow, Department of Radiology/Neurology, Memorial Sloan Kettering Cancer Center
Research Directions
1. Application of molecular imaging technique to drug development
2. Functional analysis of cancer-associated genes
Grants & Research Projects
Achievements
morefold
Social Titles
morefold
Awards & Honors
1. LI GAO Professor Fund, Chinese Academy of Sciences
morefold
Pubilcations
Full Publication List
Selected Publications
1.Guo H, Pu M, Tai Y, Chen Y, Lu H, Qiao J, Wang G, Chen J, Qi X, Huang R#, Tao Z#, Ren J#. Nuclear miR-30b-5p suppresses TFEB-mediated lysosomal biogenesis and autophagy. Cell Death Differ, 28(1), 320-36, 2021.
2.Fan X, Gensch T, Büldt G, Zhang Y, Musha Z, Zhang W, Roncarati R, Huang R. Three dimensional drift control at nano-scale in single molecule localization microscopy. Opt Express, 28(22), 32750-63, 2020.
3.Dalangood S*, Zhu Z*, Ma Z, Li J, Zeng Q, Yan Y, Shen B, Yan J#, Huang R#. Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer. Theranostics, 10(22), 10078-91, 2020.
4.Li Y*, Zhang H*, Fan L, Mou J, Yin Y, Peng C, Chen Y, Lu H, Zhao L, Tao Z, Chen J, Wang Y, Qi X, Huang R#, Ren J#. MiR-629-5p promotes the invasion of lung adenocarcinoma via increasing both tumor cell invasion and endothelial cell permeability. Oncogene, 39(17), 3473-88, 2020.
5.Li C*, Huang S*, Guo J, Wang C, Huang Z, Huang R#, Liu L, Liang S#, Wang H#. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[18F]FGln PET Imaging. Mol Imaging Biol, 21(6), 1117-26, 2019.
6.Ren W*, Zhang J*, Peng C*, Xiang H, Chen J, Peng C, Zhu W, Huang R#, Zhang H#, Hu Y#. Fluorescent Imaging of β-Amyloid Using BODIPY Based Near-Infrared Off-On Fluorescent Probe. Bioconjug Chem, 29(10), 3459-66, 2018.
7.Fang T*, Liu DD*, Ning HM*, Liu D, Sun JY, Huang XJ, Dong Y, Geng MY, Yun SF#, Yan J#, Huang RM#. Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3. Acta Pharmacol Sin, 39(12), 1885-93, 2018.
8.Huang X*, Zhu H*, Gao Z, Li J, Zhuang J, Dong Y, Shen B, Li M, Zhou H, Guo H#, Huang R#, Yan J#. Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p. J Biol Chem, 293(18), 6693-706, 2018.
morefold
Back